Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Craig R Sprenger"'
Autor:
Sailaja Puttagunta, Michael W. Dunne, Craig R. Sprenger, Chris Rubino, James Baldassarre, Scott A. Van Wart
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:1849-1855
Dalbavancin is an intravenous lipoglycopeptide with activity against Gram-positive pathogens and an MIC 90 for Staphylococcus aureus of 0.06 μg/ml. With a terminal half-life of >14 days, dosing regimens with infrequent parenteral administration beco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac01a0a480ca9daf160a5a25d3dea684
https://doi.org/10.1128/aac.04550-14
https://doi.org/10.1128/aac.04550-14
Autor:
Anna Elgart, Eli Eyal, Joel Morganroth, Craig R Sprenger, Ofer Spiegelstein, Dorit Mimrod, Emil Samara, Laura Rabinovich
Publikováno v:
Clinical pharmacology in drug development. 8(1)
In this randomized double-blind study, 4 groups of healthy subjects (50 per arm) participated to evaluate the effect of laquinimod, an oral treatment in development for multiple sclerosis and Huntington disease, on the QTc interval. Subjects received
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f373baf3329a1792f08bf99280941be
https://pubmed.ncbi.nlm.nih.gov/29786964
https://pubmed.ncbi.nlm.nih.gov/29786964
Autor:
Craig R. Sprenger, Curtis Wright, Peter G. Lacouture, Eric Lang, Douglas A. Hamilton, Donna Madden, Annie Bouchard, Daniel B. Carr, Tara McDonnell Moorehead
Publikováno v:
Clinical Therapeutics. 35(5):646-658
Background Novel formulations and administration routes of established drugs may result in higher maximum concentrations or total exposures and potentially cause previously unrecognized adverse events. Objective This study evaluated the proarrhythmic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c988f09b8e5d13970c234d5f9d2a4d85
Publikováno v:
International journal of clinical pharmacology and therapeutics. 52(3)
Aims Rasagiline is a selective, irreversible monoamine oxidase type B inhibitor, developed for the treatment of Parkinson's disease. In compliance with current regulatory requirements, rasagiline underwent a thorough QT/QTc (TQT) study to assess its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a0d0db0a082e2107349ed3593848fe9
https://pubmed.ncbi.nlm.nih.gov/24447649
https://pubmed.ncbi.nlm.nih.gov/24447649
Autor:
Milan Zdravkovic, Craig R. Sprenger, Jeffrey S. Litwin, Naum Khutoryansky, Dhruba J. Chatterjee
Publikováno v:
Journal of clinical pharmacology. 49(11)
The objective of this study was to establish effects of liraglutide on the QTc interval. In this randomized, placebo-controlled, double-blind crossover study, 51 healthy participants were administered placebo, 0.6, 1.2, and 1.8 mg liraglutide once da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b57bc435c74304236ccf3af87fd660a
https://pubmed.ncbi.nlm.nih.gov/21209241
https://pubmed.ncbi.nlm.nih.gov/21209241